Telemedicine has been available to healthcare providers for several years. However, it was not until quite recently that the field of telemedicine really took off due to the rise of the COVID-19 pandemic. With the new standard of social distancing and the burden on the healthcare system, the COVID-19 pandemic forced rapid implementation of telemedicine in day-to-day practice, resulting in the use of technology to provide healthcare growing significantly.

This overview is intended to summarise the national developments and legal frameworks with regard to telemedicine in order assist our clients in understanding their position. This document does not constitute legal advice, if you require more information please feel free to reach out to the country contacts in this document.

Read the full document here

Authored by By Katrina Dang, Johanna Harelimana, Wolfgang ErnstCarmen Miriam MartoranoHester BorgersEmma StokMarta SznajderEnrique RivasAna María Sánchez-ValdepeñasPieter ErasmusPatrick BrownJonathan Edwards

Written by
Katrina Dang
Katrina Dang
I am a junior associate, with experience advising on regulatory and commercial issues, as well as assisting in complex litigation. I have also worked in-house at a FTSE 100 pharmaceutical company. My experience spans across the firm's Intellectual Property, Commercial and Technology & Communications Groups. This exposure to different sectors has allowed me to gain experience in reviewing complex contracts and, in particular, understanding key operational clauses and how they impact upon a client's risk appetite. I have also assisted in drafting terms of use and privacy policies for clients who are entering the Australian market.
Johanna Harelimana
Johanna Harelimana
I am a junior associate, with experience advising clients on regulatory matters across several sectors, especially in life sciences, food and beverages, and environmental sectors. I currently offer both French and international clients legal advice on product's qualification, clinical trials, market access, price and reimbursement, anti-gift regulation, advertising and promotion, e-health (including telemedicine), as well as drafting contracts (distribution, professional services, clinical trial agreements, etc). I also assist with regulatory advice on other products such as cosmetics, biocide, phytopharmaceuticals and novel food.
Hester Borger
Hester Borger
As an associate in our Intellectual Property Group in The Hague, I specialise in IP law and bring my passion for technology to the fore when I'm advising our clients on their IP matters. My experience includes dispute resolution and regulatory advice. As a member of Bird & Bird's Life Sciences and Healthcare Group, I work daily on complex cross-country cases together with our other offices. In this way, we can guarantee solid advice regarding the complex challenges our clients are facing and ensure the best possible strategies and tactics in a sector that is ever-changing.
Carmen Miriam Martorano
I am an associate focused on regulatory and commercial transactions primarily in the Life Sciences and Healthcare sectors. I provide regulatory advice and assistance in commercial transactions in relation to a broad range of industries, including medicinal products, medical devices, cosmetics, sanitiser, fertilisers, and food and beverage.
Emma Stok
Emma Stok
As an associate in our Intellectual Property Group in The Hague, I offer our clients an all-round IP practice. Within our Intellectual Property Group, I advise and litigate on all areas of Intellectual Property, including patent, trade marks, trade names, product design and copyright matters. I have a special interest in both life sciences and the food industry. As part of our Life Science Regulatory group, I have contributed to international knowledge projects informing our clients of the latest regulatory developments.
Marta Sznajder
Marta Sznajder
I am a senior associate in the Intellectual Property team in Warsaw. I have been advising clients since 2012, and specialise in intellectual property law, including patent law, additional protection certificates (SPC), protection of utility and industrial designs, as well as pharmaceutical law.
Pieter Erasmus
Pieter Erasmus
I am an associate in the Intellectual Property Group in London, with a focus on regulatory and commercial matters primarily in the life sciences and healthcare sectors. Having a keen interest in all things life sciences and healthcare, I specialise primarily in providing regulatory advice in relation to a broad range of regulatory matters in these fields, including pharmaceuticals, medical devices, general healthcare, data protection/privacy (within the healthcare space and otherwise), clinical trials, marketing and advertising of health products, etc. My experience also includes providing regulatory advice in the context of other topics, including films and publications, general commercial and corporate governance, advertising and consumer protection law (regarding health products and other products), cosmetics, foodstuffs, fertilizers, farm feeds, agricultural and stock remedies, and automotive regulation.
Patrick Brown
Patrick Brown
I am an Associate in the Intellectual Property Group in Sydney, with a particular focus on the life sciences, pharmaceutical and chemical sectors. I work in the Intellectual Property Group assisting clients with a wide range of contentious and non-contentious IP matters, including patents, trade marks, plant breeder's rights and breach of confidence. I also work with clients in the life sciences, food, pharmaceutical and consumer healthcare sectors on a range of other matters including regulatory compliance, licensing and distribution agreements.
Enrique Rivas
Enrique Rivas
As a senior associate in the Regulatory & Administrative Group in our Madrid office, I am specialised in both advising and litigating for pharmaceutical, defence and technology companies in matters concerning public law, with a particular focus on public procurement. I advise on public procurement, sanctioning proceedings and liability claims against public bodies. Our clients operate mainly in three sectors, life sciences and healthcare, defence and ICT, which are strategic and particularly innovative industries.
Jonathan Edwards
Jonathan Edwards
I am an associate in our Intellectual Property Group based in London. I work with clients across the spectrum of intellectual property rights, with a particular focus on patents and intellectual property enforcement. My litigation experience to date has involved acting for clients on infringement and invalidity matters in relation to patents, copyrights and design rights. I also provide ongoing trade mark enforcement and brand protection support.
Ana María Sánchez-Valdepeñas
Ana María Sánchez-Valdepeñas
As an associate working across the Administrative Law and Regulated Sectors, I provide advice to national and international clients on all matters arising from Administrative Law. My work experience includes providing legal advice to individuals, national and international companies and public entities in many areas of Administrative Law, such as public procurement, administrative concessions, sectorial licences and authorisations, regulated sectors (such as energy, infrastructure, consumption or transport), Competition Law, the asset liability of the Public Administration and subsidies and grants.
Wolfgang Ernst
Wolfgang Ernst
I specialise in advising clients from the life sciences sector on matters at the interface between IP, unfair competition and regulatory law as well as handling complex IP litigation. My areas of practice include trademark, design and unfair competition law, but my particular specialisation is in advising clients from heavily regulated industries, most notably from the life sciences sector, but also from related sectors such as food, beverages and cosmetics. I am experienced in contentious and non-contentious matters at the interface between IP – in particular unfair competition – and regulatory law such as in matters relating to the labelling, distribution and advertising of pharmaceuticals, medical devices, food supplements and other food products.

Related articles

Bird & Bird secures win in preliminary injunction patent case before the Düsseldorf Courts
On September 26, 2019, the Higher Regional Court of Düsseldorf confirmed on appeal that Teva Pharmaceutical...
Supreme Court holds Dosage Regime Patent Obvious
Today in Actavis v ICOS the Supreme Court unanimously ruled that the ICOS patent for a Tadalafil...
New 2019 French Patent/Software box regime: taxation at a reduced rate of 10%
A new preferential taxation regime for income generated by industrial property and software is applicable...

Leave a comment

Cookie consent
We use analytics cookies to help us understand if our website is working well and to learn what content is most useful to visitors. We also use some cookies which are essential to make our website work. You can accept or reject our analytic cookies (including the collection of associated data) and change your mind at any time. Find out more in our Cookie Notice.